Coya Therapeutics (COYA) SEC Filings: History & Chart

Coya Therapeutics, Inc.(COYA)

Biotechnology · Houston, TX

$4.79-0.06 (-1.24%)

Delayed quote: Oct 6, 2026, 10:19 AM EDT

About Coya Therapeutics, Inc.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

8 employees

www.coyatherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arun Swaminathan

View full financials

Form	Filing Date	Accepted	Document
8-K	Oct 5, 2026	Oct 5, 2026	View filing
8-K	Sep 15, 2026	Sep 15, 2026	View filing
10-Q	Aug 11, 2026	Aug 11, 2026	View filing
8-K	Aug 11, 2026	Aug 11, 2026	View filing
8-K/A	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G/A	Jul 27, 2026	Jul 27, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
ARS	May 13, 2026	May 13, 2026	View filing
DEFA14A	May 13, 2026	May 13, 2026	View filing
DEF 14A	May 13, 2026	May 13, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
424B5	May 12, 2026	May 12, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
4	Apr 9, 2026	Apr 9, 2026	View filing
3	Apr 9, 2026	Apr 9, 2026	View filing
8-K	Apr 2, 2026	Apr 2, 2026	View filing
EFFECT	Mar 20, 2026	Mar 23, 2026	View filing
424B3	Mar 20, 2026	Mar 20, 2026	View filing
S-3	Mar 16, 2026	Mar 16, 2026	View filing
10-K	Mar 16, 2026	Mar 16, 2026	View filing
8-K	Mar 16, 2026	Mar 16, 2026	View filing
SC 13G	Mar 12, 2026	Mar 12, 2026	View filing
SC 13G/A	Jan 30, 2026	Jan 30, 2026	View filing
8-K	Jan 30, 2026	Jan 30, 2026	View filing
SC 13G/A	Jan 28, 2026	Jan 28, 2026	View filing
4	Jan 26, 2026	Jan 26, 2026	View filing
4	Jan 26, 2026	Jan 26, 2026	View filing
4	Jan 26, 2026	Jan 26, 2026	View filing
4	Jan 26, 2026	Jan 26, 2026	View filing

SEC Filings

Recent Filings